AMR SVG Icons location

Cyanocobalamin (B12)Injection, USP


  • “AP” Rated1
  • Vial closure is not made with rubber latex
  • Preserved with 1.5% Benzyl Alcohol

Receive Availability Emails

  NDC# Strength Supplied As Shelf Pack Product Info Availability
Strength:

1000 mcg/mL

Supplied As:

1 mL Vial

NDC#: 0517-0031-25
0517-0031-25

1000 mcg/mL

1 mL Vial

25 In Stock
  • Shelf Pack 25
  • Availability In Stock

Wholesaler Numbers

  • ABC/SAP 10003480
  • Cardinal 2529212
  • HD Smith 1073931
  • McKesson 1310242
  • Morris & Dickson 780171

Case Information

  • Unit of Sale NDC 0031-25
  • Order Size 25
  • Case Size 90
  • Case Per Tier 40
Strength:

1000 mcg/mL

Supplied As:

30 mL
Multiple Dose Vial

NDC#: 0517-0130-01
0517-0130-01

1000 mcg/mL

30 mL
Multiple Dose Vial

1 In Stock
  • Shelf Pack 1
  • Availability In Stock

Wholesaler Numbers

  • ABC/SAP 10048103
  • Cardinal 3453719
  • HD Smith 1459486
  • McKesson 1984673
  • Morris & Dickson 476101

Case Information

  • Unit of Sale NDC 0130-01
  • Order Size 1
  • Case Size 192
  • Case Per Tier 32
Strength:

1000 mcg/mL

Supplied As:

10 mL
Multiple Dose Vial

NDC#: 0517-0032-25
0517-0032-25

1000 mcg/mL

10 mL
Multiple Dose Vial

25 Limited Supply
  • Shelf Pack 25
  • Availability Limited Supply

Wholesaler Numbers

  • ABC/SAP 10036540
  • Cardinal 1193689
  • HD Smith 5171020
  • McKesson 1621986
  • Morris & Dickson 104752

Case Information

  • Unit of Sale NDC 0032-25
  • Order Size 25
  • Case Size 16
  • Case Per Tier 64

1Approved Drug Products with Therapeutic Equivalence Evaluations. Reference: 1. Approved Drug Products with Therapeutic Equivalence Evaluations.
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=080737
Accessed August 21, 2018.

Contact Us

Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact
Rx Only For intramuscular or deep subcutaneous injection. Avoid using the intravenous route. INDICATIONS AND USAGE Cyanocobalamin is indicated for vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions:
  • Addisonian (pernicious) anemia
  • Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue,
    small bowel bacteria overgrowth, total or partial gastrectomy
  • Fish tapeworm infestation
  • Malignancy of pancreas or bowel
  • Folic acid deficiency
It may be possible to treat the underlying diseases. Cyanocobalamin Injection, USP is also suitable for the vitamin B12 absorption test (Schilling test). Use of this product intravenously will result in almost all of the vitamin being lost in the urine. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Sensitivity to cobalt and/or vitamin B12 is a contraindication. WARNINGS Patients with early Leber’s disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy. Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely. Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. An intradermal test dose is recommended before Cyanocobalamin Injection, USP is administered to patients suspected of being sensitive to this drug. This product contains Benzyl Alcohol. Benzyl Alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants. This product contains aluminum that may be toxic. Precautions Doses of cyanocobalamin exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency. Laboratory Tests During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary. Hematocrit, reticulocyte count, vitamin B12, folate and iron levels should be obtained prior to treatment. Hematocrit and reticulocyte counts should be repeated daily from the fifth to seventh days of therapy and then frequently until the hematocrit is normal. Patients with pernicious anemia have about 3 times the incidence of carcinoma of the stomach as the general population, so appropriate tests for this condition should be carried out when indicated. Drug Interactions Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays. Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12. Pregnancy Category C Adequate and well-controlled studies have not been done in pregnant women. However, vitamin B12 is an essential vitamin and requirements are increased during pregnancy. Nursing Mothers: Vitamin B12 is known to be excreted in human milk. ADVERSE REACTIONS Generalized: Anaphylactic shock and death which have been reported with administration of parenteral vitamin B12 Cardiovascular: Pulmonary edema and congestive heart failure early in treatment; peripheral vascular thrombosis Hematological: Polycythemia vera Gastrointestinal: Mild transient diarrhea Dermatological: Itching; transitory exanthema Miscellaneous: Feeling of swelling of entire body For additional Safety Information, please see Full Prescribing Information. You are encouraged to report Adverse Drug Events (ADEs) to American Regent Inc. at 1-800-734-9236
or to the FDA by visiting www.fda.gov/MedWatch or calling 1-800-FDA-1088.